Eisai requests EMA authorization for Lenvatinib as 1st line treatment of hepatocarcinoma


               Eisai has announced permission to market lenvatinib as a first-line treatment in patients with unresectable hepatocellular carcinoma (CHCi). Patients with hepatocellular carcinoma have a poor prognosis, with a complex disease responsible for approximately 90% of liver cancer cases worldwide.           “For a decade there has been no breakthrough in the first-line systemic treatment [ ] The post Eisai requests EMA authorization for Lenvatinib as 1st line treatment of hepatocarcinoma appeared first on STL News.
http://bit.ly/2uiJwX1

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s